Skip to main content
Clinical Trials/NCT03477071
NCT03477071
Completed
Not Applicable

A 15-year Single Center Experience of Endovascular Treatment of Transplant Renal Artery Stenosis: Evaluation of Post-operative Outcomes

Centre Hospitalier Universitaire de Nice0 sites1,323 target enrollmentJanuary 1, 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Unrecognized Condition
Sponsor
Centre Hospitalier Universitaire de Nice
Enrollment
1323
Primary Endpoint
The technical success rate of endovascular treatment
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

Stenosis of the renal graft arteries occurs in 1 to 26% of cases and can damage the graft. Endovascular treatment is first-line treatment. The main objective of this study is to identify the predictive factors of failure of peri-anastomotic.

Detailed Description

The aim of this study was to evaluate the post-operative outcomes following endovascular treatment of TRAS (Transplant Renal Artery Stenosis). This retrospective, monocentric study included patients with peri-anastomotic stenosis of the renal graft from 2000 to 2017. The stenosis is defined by a reduction of at least 50% of the arterial diameter during arteriography. Technical success was defined as residual stenosis less than 30% of the arterial diameter after the procedure.

Registry
clinicaltrials.gov
Start Date
January 1, 2010
End Date
December 1, 2017
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • All patients who had a renal transplant from brain-dead donors or from living donors
  • All patients who had a Transplant Renal Artery Stenosis

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

The technical success rate of endovascular treatment

Time Frame: 30 days

The stenosis is defined by a reduction of at least 50% of the arterial diameter during arteriography. Technical success was defined as residual stenosis less than 30% of the arterial diameter after the procedure

Secondary Outcomes

  • Mortality rate(30 days)
  • Morbidity rate(30 days)

Similar Trials